To assess the clinical relevance of NRF2 pathway activation in OAC primary tumours, we employed four NRF2 targets (KIAA0319, ARID3A, HSPA1B, PTGR1) from clusters 2 and 9 to calculate the risk score based on datasets from The Cancer Genome Atlas (TCGA). This evidence concerns the gene NFE2L2 and neoplasm.